Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde 3-phosphate dehydrogenase pseudogene 42 (GAPDHP42) is classified as a pseudogene—an inactive genomic DNA segment similar to the functional GAPDH gene, which encodes an enzyme central to glycolysis and multiple cellular processes[1][2]. Pseudogenes such as GAPDHP42 do not encode functional proteins due to disrupting mutations or regulatory changes and therefore do not have independent biological or therapeutic relevance[3][5]. Multiple GAPDH-related pseudogenes exist in the human genome and may occasionally be used in research as reference sequences, but GAPDHP42 is not a known therapeutic, diagnostic, or druggable target[3][5]. If information about a druggable, functional protein target is needed, refer to the **canonical GAPDH gene** rather than any of its pseudogenes[1][2].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde 3-phosphate dehydrogenase pseudogene 42 (GAPDHP42).